Australia is the first country to allow patients with depression or PTSD to prescribe psychedelics

SYDNEY (AP) Australia is now the first country to allow psychiatrists to prescribe certain psychedelics to patients with depression or PTSD.

Starting Saturday, Australian doctors can prescribe doses of MDMA, also known as ecstasy, for PTSD. Psilocybin, the psychoactive ingredient in psychedelic mushrooms, can be administered to people suffering from difficult-to-treat depression. The country has placed the two drugs on the list of medicines approved by the Therapeutic Goods Administration.

Scientists in Australia were surprised by the move, which was announced in February but went into effect on July 1. One scientist said he puts Australia at the forefront of research in this field.

Australian Prime Minister Anthony Albanese has criticized Hong Kong authorities for going after two pro-democracy activists living in Australia.

Business travel for Indonesians to Australia will be facilitated in a bid to strengthen the economic partnership between the two countries following an agreement reached between their leaders.

Australia’s central bank left its benchmark interest rate at 4.1% after inflation fell to 5.6% in May from 6.5% the previous month.

Asian stock markets are mixed after Wall Street hit a 15-month high ahead of an Australian central bank decision on a possible interest rate hike.

Chris Langmead, deputy director of the Neuromedicines Discovery Center at the Monash Institute of Pharmaceutical Sciences, said there has been very little progress in treating persistent mental health problems over the past 50 years.

Growing cultural acceptance has led two US states to pass measures for their use: Oregon was the first to do so legalize the use of psilocybin by adultsand Colorado voters decriminalized psilocybin in 2022. Days ago, President Joe Bidens the younger brother said in a radio interview that the president has been very open in the conversations the two have had about the benefits of psychedelics as a form of medical treatment.

The U.S. Food and Drug Administration designated psilocybin a Breakthrough Therapy in 2018, a label designed to expedite the development and review of drugs to treat a serious condition. Psychedelic researchers have received federal grants, including Johns Hopkinsand the FDA has released draft guide late last month for researchers planning clinical trials testing psychedelic drugs as potential treatments for a variety of medical conditions.

Again, the American Psychiatric Association did not approve of the use of psychedelics in treatmentnoting that the FDA has yet to offer a final determination.

And medical experts in the United States and elsewhere, including Australia, have warned that more research is needed into the effectiveness of drugs and the extent of the risks of psychedelics, which can cause hallucinations.

There are concerns that the evidence remains inadequate and that the transition to clinical service is premature; that incompetent or poorly equipped doctors could flood the space; that treatment will be untenable for most; that formal oversight of education, treatment and patient outcomes will be minimal or ill-informed, said Dr. Paul Liknaitzky, head of the Clinical Psychedelic Lab at Monash University.

In addition, the drugs will cost Australia about $10,000 (about $6,600 US dollars) per patient to treat.

Litnaitzky said the opportunity for Australians to access medicines for specific conditions is unique.

There is excitement about drug policy advances, he said, ‘…for the prospect of being able to offer patients more tailored and tailored treatment without the constraints imposed by clinical trials and rigid protocols.